Industries

Agricultural Sciences and Technology

From seed to scale, Cooley powers agtech innovators and their investors with legal and regulatory insight, intellectual property protection and market access

Sentera Acquired by John Deere

May 23, 2025

Cooley advised Sentera, a leading provider of remote imagery solutions for agriculture, on its acquisition by John Deere. Sentera’s industry-leading cameras are compatible with most major drone platforms, enabling farmers and crop scouts to quickly and efficiently capture high-resolution data at scale. The cameras’ capabilities and Sentera’s FieldAgent software tools help farmers and agronomists assess plant-level health, identify stressors and take action.

This acquisition will advance the capabilities of John Deere’s existing tech offerings, providing farmers and ag service providers with a more comprehensive set of tools to generate and use data to make decisions that improve farm profitability, efficiency and sustainability.

Related contacts

Dr. Chris Holly
Partner, Washington, DC
Erin J. Kirchner
Partner, Chicago
Megan E. Bowles
Associate, Chicago
Adam Bloom
Associate, Chicago
Emma Frerichs
Associate, Chicago

Related Practices & Industries

Decibel Bio Closes $12 Million Financing Round

March 5, 2025

Cooley advised Decibel Bio, a plant biotechnology company building the world’s first crop epigenetic platform, on its $12 million financing round. The funding will be used to advance Decibel’s proprietary platform for both reading and writing the plant epigenome to create crop varieties with higher yield, efficiency and resilience to a changing environment.

Related contacts

Frederick Dorey
Special Counsel, Palo Alto
Katie Weeks
Associate, Palo Alto

Related Practices & Industries

Jord BioScience Closes $7 Million Series B Financing

February 19, 2025

Cooley advised Jord BioScience on its $7 million Series B financing round, including the intellectual property due diligence in connection with the deal. The funding round will accelerate Jord BioScience’s development and commercialization of its microbial technologies to deliver next-generation crop inputs.

Related contacts

Dr. Chris Holly
Partner, Washington, DC
Dr. Elizabeth Magnotti Baez
Associate, Washington, DC

Related Practices & Industries

Cooley advises Pivot Bio on $100M Series C Round

May 4, 2020

Cooley advised California-based agricultural biotech growth company Pivot Bio on its $100 million Series C funding round, co-led by repeat investors Breakthrough Energy Ventures and a global investment company. Pivot Bio has raised $186 million to date and plans to use the funds to scale-up its microbial nitrogen technology that helps farmers boost crop yield and reduce reliance on synthetic nitrogen fertilizer. The funding will also be used to help the company expand internationally. "The strong backing by our Series C investors enables Pivot Bio to redefine the future of fertilizer and provide the world's farmers with a new nitrogen source. Based on remarkable demand, we expect to ramp up from our large current footprint to millions of additional acres in the next growing season." said Karsten Temme, Ph.D., CEO and co-founder of Pivot Bio, in a news release.

Related contacts

Frederick Dorey
Special Counsel, Palo Alto
John Sellers
Senior Counsel, Palo Alto
Emily Iannarelli
Associate, Palo Alto
Lauren Creel
Partner, Palo Alto
Dr. Chris Holly
Partner, Washington, DC
Judd Lauter
Special Counsel, San Francisco

CBD Leader Charlotte’s Web successfully enforces trademark

April 2, 2021

Cooley secured a successful resolution for Charlotte’s Web, a leader in the hemp-based cannabidiol (CBD) industry, in a federal trademark and false advertising dispute with AAXLL Supply Co, owner of the Balance CBD brand, in the Northern District of California. Charlotte's Web filed a complaint against AAXLL on April 17, 2020 in which it alleged that AAXLL infringed Charlotte's Web's rights in its CHARLOTTE'S WEB trademark and had misrepresented that certain AAXLL products shared a terpene profile with hemp cultivars developed by Charlotte's Web. Under a stipulated judgment, AAXLL acknowledged that the CHARLOTTE'S WEB mark is a valid and protectable trademark, all rights, title and interest to which are owned by Charlotte’s Web. AAXLL further admitted to trademark infringement and also agreed to stop using the CHARLOTTE'S WEB trademark in connection with advertising and promoting CBD products.

Related contacts

Brendan Hughes
Co-Partner in Charge – Washington, DC, Washington, DC
John Paul Oleksiuk
Partner, New York
Judd Lauter
Special Counsel, San Francisco
Colleen R. Wellington-Caban
Associate, Washington, DC

Related Practices & Industries

Momofuku Goods Raises $17.5 Million in Series A Financing

April 13, 2023

Cooley advised Momofuku Goods, a brand of restaurant-grade pantry staples, on its $17.5 million Series A financing led by Siddhi Capital. The new funding will allow Momofuku to expand product offerings and support its growing operations, which includes scaling its team and marketing efforts.

“We spent a decade testing and developing our pantry essentials, ensuring that they were up to the standards we uphold in our restaurants,” David Chang, celebrity chef and founder of Momofuku restaurant group, said in a press statement. “With this investment, I’m looking forward to bringing even more flavor to home cooks’ kitchens.” Founded by the team behind Momofuku restaurants, Momofuku Goods offers a range of products, including chili crunch oil, air-dried noodles, soy sauce, rice vinegar and seasoned salts that are sold online and in more than 2,000 retail stores.

Winston Gu and Yvan-Claude Pierre led the Cooley team, which also included Len Jacoby, JP Oleksiuk, Jonathan Rivinus, Robert Eisenbach, Joyce Kim, Chris Chynoweth, Andrew Mettry, Bomin Kim and Noah Belsky.

Related contacts

Yvan-Claude Pierre
Partner, New York
Len Jacoby
Partner, New York
John Paul Oleksiuk
Partner, New York
Jonathan Rivinus
Partner, Colorado
Robert Eisenbach
Of Counsel, San Francisco
Chris Chynoweth
Special Counsel, New York
Andrew Mettry
Associate

Cooley Advises AgroSpheres on Series B Financing

April 24, 2023

Cooley advised AgroSpheres on its $22 million Series B financing and led intellectual property due diligence in connection with the round. Cooley counsels AgroSpheres with respect to corporate matters and is the architect behind development of the company’s ever-expanding patent portfolio.

AgroSpheres’ biomanufacturing platform enables cost-effective manufacturing and successful field application of novel biological modalities. The unprecedented field success of foliar-applied AgriCell-RNAi technologies has garnered significant industry interest.

“In this unprecedented bear market, food security, environmental footprint, and supply chain resilience are of paramount importance,” said Payam Pourtaheri, founder and CEO of AgroSpheres. “We are thankful for the support from our partners at Lewis & Clark, OAS, Bidra, and Cavallo, as we take significant strides towards our vision of a future built by nature’s technologies and bring our biobased technologies to partners globally.”

Related contacts

Dr. Chris Holly
Partner, Washington, DC

Related Practices & Industries

Cooley advises food industry pioneer Nobell Foods on patent matters

July 27, 2021

Cooley has served as primary IP counsel to Nobell Foods since its founding, helping the company to protect its innovative contributions aimed at making the world’s food systems more humane and sustainable. Nobell Foods is utilizing the power of plants to reimagine the world’s food supply and produce delicious cheese from plant-derived dairy proteins. The company recently completed a $75 million Series B in 2021 to help bring its vision to the world.

Related contacts

Dr. Chris Holly
Partner, Washington, DC

Related Practices & Industries

Why Cooley

  • Decades spent driving agtech innovation

    Cooley’s lawyers have advanced the agricultural sciences landscape for decades, blending deep technical knowledge with commercial acumen. Our clients are industry pioneers and disruptors, from startups and global public companies to the investors backing game-changing technologies in the agricultural biotechnology, microbial engineering, microbiome, and food, animal and plant sciences industries.

  • Unrivaled legal platform for agtech visionaries

    Our robust, full-service agtech platform supports innovators at every stage of the business cycle, providing counsel on market entry, regulatory compliance, investigations and litigation. Our team’s 40+ years at the US Food and Drug Administration’s Office of the General Counsel helps clients see around corners and get ahead of risks before they surface.

  • Connected to industry influencers

    Our clients tap into one of the largest and most influential networks of venture capital firms, financial institutions and other strategic partners.

  • Holistic strategy integrating IP, corporate, regulatory and more

    We build defensible, diligence-ready IP portfolios aligned with business objectives, integrating patent, corporate, litigation, partnering and regulatory strategy. Our “whole of government” approach is proven – hundreds of times over.

Read more

Cooley [lawyers] are very commercial-minded.

Chambers Global, 2025

Recognition

  • Chambers: Global Market Leader: Agribusiness (2026)
  • Chambers USA: Band 1 for Startups and Emerging Companies (2025)
  • Chambers USA: Intellectual Property – Nationwide (2025)
  • BTI: Litigation Powerhouse (2026)
  • The Legal 500 US: Tier 1 for Venture Capital and Startups (2025)
  • LMG Life Sciences EMEA: Licensing and Collaboration Firm of the Year (2025)
  • LMG Life Sciences: Patent Strategy and Management Firm of the Year – Honoree (2023)
  • Managing IP: Ranked for Trademark Disputes and Prosecution (2024)
  • PitchBook: #1 law firm for VC-backed exits – IPO and M&A (2025)
  • World Trademark Review: Gold Tier for Trademark Law (2025)

Frequently asked questions

What is the focus of Cooley’s agricultural sciences and technology practice?

Cooley’s agricultural sciences and technology practice empowers agtech, foodtech and life sciences companies and their investors with end‑to‑end legal support. We guide innovators through market entry, financing, IP protection and regulatory strategy, and help them commercialize technologies spanning next‑generation plant breeding, biological inputs, microbial engineering, precision agriculture, and data‑driven crop and food system solutions.

What industries and technologies does Cooley’s agtech team work with?

Cooley advises clients advancing a spectrum of agricultural, biological and digital technologies – including genomic engineering tools (CRISPR, RNAi, base editing, TALENs), gene‑edited crops, predictive crop modeling, remote sensing, microbial compositions and treatments, agricultural biologicals, microbiome‑modulation platforms, recombinant microbes, nitrogen‑fixation technologies, alternative proteins, biofuels, synthetic biology, insect pheromone systems, and natural or organic crop protection solutions. Our experience spans row crops, specialty crops, horticulture and emerging food systems.

How does Cooley help clients navigate international regulatory and IP challenges?

Cooley helps agtech companies navigate complex regulatory and IP landscapes with practical, risk‑based guidance shaped by former FDA enforcement attorneys and lawyers with significant European Union regulatory insight. Our team supports clients developing advanced technologies – such as gene‑edited plants, microbial and biological products, bio‑based formulations, feed and food compositions, and new plant varieties – building diligence‑ready IP portfolios and guiding companies through US and international compliance requirements.

How does Cooley support agtech innovators and investors throughout the business life cycle?

Cooley supports agtech innovators and investors at every stage – from company formation and venture financing to IP portfolio development, strategic transactions, regulatory strategy and high-stakes litigation. Our cross‑disciplinary platform helps companies scale technologies, such as microbial engineering, high‑tech precision agriculture, next‑generation plant breeding, horticultural and floriculture innovation, alternative proteins and sustainable biological solutions, while connecting them to one of the most influential networks of venture capital firms and strategic partners in the agricultural sciences sector.

What makes Cooley unique in the agricultural sciences and technology sector?

Cooley combines scientific fluency with commercial and regulatory depth. With decades of FDA experience, a leading venture capital and emerging companies platform, and one of the largest life sciences IP teams in the US, we help clients safeguard transformative technologies – from crop genetics and microbial treatments to synthetic biology, biofuels and advanced biological inputs. Our integrated approach enables clients to anticipate risk, accelerate growth and compete confidently in rapidly evolving global markets.

Life sciences resources

From startup to scale, our industry resources equip life sciences leaders with curated insights on regulatory developments, financing trends, IP strategies and key legal considerations shaping the life sciences landscape

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.